Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNano Genomics Inc (BNGO) vs ArcelorMittal SA (MT) Price & Performance

BioNano Genomics IncTrade
ArcelorMittal SATrade

Price performance (Past 24H)

Key statistics

BioNano Genomics Inc vs ArcelorMittal SA — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while ArcelorMittal SA trades at $67.56 (market cap $50.59B). The key difference: ArcelorMittal SA is far larger — about 3832.6× BioNano Genomics Inc's market cap, and ArcelorMittal SA pays a 0.9% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.

BNGOMT
Market Cap
$13.20M$50.59B
Sector
HealthBasic Materials
52-Week High
$4.92$71.65
52-Week Low
$1.09$30.39
Enterprise Value
$15.81M$59.91B
Dividend Yield
0.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNano Genomics Inc

Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.

BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.

ArcelorMittal SA

ArcelorMittal (MT) trades at $65.92, down 0.24% today, with a bullish technical outlook and strong recent earnings beats. The stock shows robust fundamentals with a P/E of 17.26 and P/S of 0.81, supported by a net income margin of 4.71% and consistent dividend payments. Recent news highlights expansion initiatives and a strategic AI collaboration with AWS, driving positive sentiment amid a 41% six-month gain (Zacks Investment Research, 2026-06-23).

Outlook remains positive with analyst consensus at 50% buy ratings, though risks include cyclical steel demand and high capital expenditure. The stock's valuation appears reasonable, but investors should monitor global economic conditions and steel pricing trends for sustained growth.

Returns comparison

Trailing returns across standard periods

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO

About ArcelorMittal SA

ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA

Read more on MT